Biologics such as TNF inhibitors (e.g., infliximab and adalimumab) and integrin inhibitors have demonstrated unequivocal efficacy in inducing and maintaining remission in moderate-to-severe IBD, reducing the frequency of flare-ups and hospitalizations (39, 40). This evidence concerns the gene TNF and inflammatory bowel disease.